Researchers at Weill Cornell Medicine and the Burke Neurological Institute have made an exciting discovery—a new drug that ...

Mean daily gabapentin dose increased during the first year of use and was higher in the neuropathic pain group than in the pruritus group: 503 vs 433 mg. Drug discontinuation occurred earlier in ...

The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing ... On Day 9, at the optimal dose of 300 mg/kg, Ketamir ...

The firm says it could offer an alternative to existing treatments while sidestepping addiction concerns that have plagued ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...

Magnesium should not be taken with certain medications, including some antibiotics, diabetes drugs, diuretics, and others.

MIRA Pharmaceuticals (MIRA, Financial) shares soared by 40% after the company achieved a significant breakthrough in ...

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be ...

Managing neuropathic pain in these patients remains ... existing treatments like FDA-approved gabapentin and pregabalin, which often come with side effects such as cognitive impairment, weight ...

MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...